COVID-19 disease severity and death in relation to vitamin D status among SARS-CoV-2-positive UAE residents by Alsafar, Habiba et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2021 
COVID-19 disease severity and death in relation to vitamin D 
status among SARS-CoV-2-positive UAE residents 
Habiba Alsafar 




See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Dietetics and Clinical Nutrition Commons, and the Diseases Commons 
10.3390/nu13051714 
AlSafar, H., Grant, W. B., Hijazi, R., Uddin, M., Alkaabi, N., Tay, G., ... Al Anouti, F. (2021). COVID-19 disease severity 
and death in relation to vitamin D status among SARS-CoV-2-positive UAE residents. Nutrients, 13(5), article 1714. 
https://doi.org/10.3390/nu13051714 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/10379 
Authors 
Habiba Alsafar, William B. Grant, Rafiq Hijazi, Maimunah Uddin, Nawal Alkaabi, Guan Tay, Bassam 
Mahboub, and Fatme Al Anouti 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/10379 
nutrients
Article
COVID-19 Disease Severity and Death in Relation to Vitamin D
Status among SARS-CoV-2-Positive UAE Residents
Habiba AlSafar 1,2,3,† , William B. Grant 4 , Rafiq Hijazi 5 , Maimunah Uddin 6 , Nawal Alkaabi 6,
Guan Tay 1,7,8 , Bassam Mahboub 9 and Fatme Al Anouti 10,*,†


Citation: AlSafar, H.; Grant, W.B.;
Hijazi, R.; Uddin, M.; Alkaabi, N.; Tay,
G.; Mahboub, B.; Al Anouti, F.
COVID-19 Disease Severity and
Death in Relation to Vitamin D Status
among SARS-CoV-2-Positive UAE
Residents. Nutrients 2021, 13, 1714.
https://doi.org/10.3390/nu13051714
Academic Editor: Karl Michaëlsson
Received: 5 May 2021
Accepted: 17 May 2021
Published: 19 May 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Center for Biotechnology, Khalifa University of Science and Technology,
Abu Dhabi 127788, United Arab Emirates; habiba.alsafar@ku.ac.ae (H.A.); guan.tay@uwa.edu.au (G.T.)
2 Department of Biomedical Engineering, College of Engineering,
Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates
3 Department of Genetics and Molecular Biology, College of Medicine and Health Sciences,
Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates
4 Sunlight, Nutrition and Health Research Center, P.O. Box 641603, San Francisco, CA 94164-1603, USA;
williamgrant08@comcast.net
5 Department of Mathematics and Statistics, College of Natural and Health Sciences, Zayed University,
Abu Dhabi 144534, United Arab Emirates; Rafiq.Hijazi@zu.ac.ae
6 Department of Pediatric Infectious Disease, Sheikh Khalifa Medical City,
Abu Dhabi 51900, United Arab Emirates; muddin@seha.ae (M.U.); nalkaabi@seha.ae (N.A.)
7 Division of Psychiatry, Faculty of Health and Medical Sciences, University of Western Australia,
Crawley, Western Australia, Australia
8 School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
9 Dubai Health Authority, Rashid Hospital, Dubai, United Arab Emirates; drbassam_mahboub@yahoo.com
10 Department of Health Sciences, College of Natural and Health Sciences, Zayed University,
Abu Dhabi 144534, United Arab Emirates
* Correspondence: Fatme.AlAnouti@zu.ac.ae
† These authors contributed equally to this work.
Abstract: Insufficient blood levels of the neurohormone vitamin D are associated with increased risk
of COVID-19 severity and mortality. Despite the global rollout of vaccinations and promising prelim-
inary results, the focus remains on additional preventive measures to manage COVID-19. Results
conflict on vitamin D’s plausible role in preventing and treating COVID-19. We examined the relation
between vitamin D status and COVID-19 severity and mortality among the multiethnic population of
the United Arab Emirates. Our observational study used data for 522 participants who tested positive
for SARS-CoV-2 at one of the main hospitals in Abu Dhabi and Dubai. Only 464 of those patients
were included for data analysis. Demographic and clinical data were retrospectively analyzed. Serum
samples immediately drawn at the first hospital visit were used to measure serum 25-hydroxyvitamin
D [25(OH)D] concentrations through automated electrochemiluminescence. Levels < 12 ng/mL were
significantly associated with higher risk of severe COVID-19 infection and of death. Age was the
only other independent risk factor, whereas comorbidities and smoking did not contribute to the
outcomes upon adjustment. Sex of patients was not an important predictor for severity or death. Our
study is the first conducted in the UAE to measure 25(OH)D levels in SARS-CoV-2-positive patients
and confirm the association of levels < 12 ng/mL with COVID-19 severity and mortality.
Keywords: vitamin D; COVID-19; SARS-CoV-2; severity; mortality; United Arab Emirates
1. Introduction
COVID-19 is a complex respiratory syndrome caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), an enveloped RNA virus extremely transmissible
through respiratory aerosols [1]. This virus, which can lead to pulmonary failure and
fatality, has a noticeable genetic similarity to the beta-coronaviruses that cause SARS and
Middle East respiratory syndrome [2]. The clinical indications of COVID-19 disease range
Nutrients 2021, 13, 1714. https://doi.org/10.3390/nu13051714 https://www.mdpi.com/journal/nutrients
Nutrients 2021, 13, 1714 2 of 14
from asymptomatic to mild to severe. Although most affected patients develop mild
symptoms, about 5% of cases might progress to acute respiratory distress syndrome, re-
quiring hospitalization and intensive care [3]. Elevated oxidative stress levels, exaggerated
immune response due to the cytokine storm, and uncontrollable liberation of proinflam-
matory cytokines, along with the activation of pre-coagulating factors, all contribute to
severe inflammation, which is exaggerated in acute respiratory distress syndrome [4,5].
Vitamin D is a fat-soluble prohormone steroid that has endocrine, paracrine, and autocrine
functions [6]. Recent studies demonstrated that vitamin D could mediate antiviral activity
by many actions, including enhancing apoptosis and autophagy as well as by inducing
antimicrobial peptides [7,8].
Accumulating evidence has shown that severe disease is high among vulnerable
populations: the elderly and patients with chronic diseases such as asthma, cancer, chronic
obstructive pulmonary disease, diabetes, and hypertension. People who are obese or
belong to ethnic groups with darker skin also experience more severe disease [9,10].
To fully decipher the mechanism underlying COVID-19 disease susceptibility, re-
searchers are considering several possible contributing factors [11]. Vitamin D deficiency
has emerged as a leading candidate [7,12,13]. Although concrete evidence about vitamin
D’s therapeutic role in COVID-19 has yet to be confirmed through randomized controlled
trials (RCTs), vitamin D is associated with protective effects [7]. Such effects arise because
vitamin D, as an essential prohormone that maintains bone homeostasis, also mediates
many important non-skeletal functions, including modulating the immune system [14].
Several studies have documented the correlation between vitamin D deficiency and
severity of viral infections such as influenza [15]. A study among children and adolescents
indicated a higher risk of viral respiratory tract infections with deficient and insufficient
serum 25-hydroxyvitamin D [25(OH)D] levels [16]. Moreover, a meta-analysis by Mar-
tineau and colleagues of RCTs across the globe including 11,321 participants showed that
vitamin D-deficient patients had better protection against respiratory tract infections after
supplementation with vitamin D (odds ratio (OR) = 0.30; 95% confidence interval (CI), 0.17,
0.53) [17]. Recently, vitamin D was identified by genomics-guided tracing research to be
involved in regulating gene expression with potential to alleviate SARS-CoV-2 infection
upon binding to the vitamin D response element [18]. The well-established role of vitamin
D as an anti-inflammatory agent explains the beneficial effect of vitamin D in both the
innate and adaptive immune responses and in producing antimicrobial agents cathelicidin
(LL-37) and human β-defensin 2 [19,20].
Moreover, vitamin D regulates the renin–angiotensin system and expression of
angiotensin-converting enzyme 2 (ACE2), and the corresponding cell receptor, which
mediates coronavirus infection (ACE2 and the ACE2 receptor are distinct, and ACE2 seems
able to bind SARS-CoV-2, preventing it from attaching to the ACE2 receptor). Elevated
expression of ACE2 had been linked to a protective effect in the lungs during acute injury.
Higher expression also reduces infectivity of SARS-CoV-2 by attenuating attachment to
ACE2 receptors in target cells [21,22].
A previous study that examined the expression pattern for ACE2 in a mouse model in
the context of aging and sex showed a significantly downregulated expression for ACE2
in older female and male rats, by 67% and 78%, respectively [23]. That decrease of ACE2
protein accords with the reported higher risk of COVID-19 infection and severity of disease
among males [22]. Vitamin D also strengthens the epithelial physical barrier through
its effect on E-cadherin, which tightens the cellular junctions to be tight and effective
in impeding viral particles from penetrating the lungs [20]. Evidence from studies in
20 European countries showed that 25(OH)D concentrations and COVID-19 mortality were
inversely associated, as well as that vitamin D deficiency was a poor prognostic factor for
COVID-19. Severe vitamin D deficiency was remarkably evident among the elderly [24].
A systematic review and meta-analysis of 14 studies from an observational prospec-
tive and retrospective investigation with 999,179 participants indicated that low serum
25(OH)D was associated with higher susceptibility for COVID-19 infection and more se-
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vere disease and mortality [25]. Ongoing clinical trials for assessing the role of vitamin
D supplementation in treating COVID-19 infections are under way, and the results so far
have shown potential for using vitamin D supplementation, particularly for intensive care
patients [26].
Mounting evidence from retrospective studies conducted in the United States and
Europe indicates that lower vitamin D levels are commonly associated with risk of ac-
quiring, and dying from, COVID-19 among hospitalized patients. Low levels may have
some role in determining severity and outcome of COVID-19 [27]. Moreover, vitamin D
deficiency is highly prevalent among critically ill patients and could aggravate the clinical
outcome of those vulnerable people by increasing infection rates and mortality [28,29].
Supplementation with vitamin D for those susceptible people plays a pivotal role in helping
them recover through supporting the immune system [30,31]. Despite the global rollout
of vaccinations, the focus is still on additional promising preventive measures, such as
using vitamin D to manage COVID-19 [32]. Vitamin D deficiency is a major public health
burden in the Middle East, including the United Arab Emirates (UAE), despite abundant
year-round sunlight [33–35].
Our objective was to assess the association of vitamin D status with COVID-19 disease
severity and mortality in a sample of SARS-CoV-2-positive people from the UAE population.
The multiethnic differences among the UAE population together with the unique pattern
of COVID-19 mortality and severity in the country merit further investigation.
We used Our World in Data (Stats. WHO 2021), an online interactive dashboard
hosted by Johns Hopkins University, to track reported COVID-19 cases in real time
(https://coronavirus.jhu.edu/map.html accessed on 26 April 2021).
2. Materials and Methods
2.1. Participants and Collecting Samples
This study was a multicenter observational study with data collected between August
2020 and February 2021. We recruited 522 participants in the UAE who tested positive
for SARS-CoV-2 during a COVID-19 screening at either Sheikh Khalifa Medical Centre
in Abu Dhabi, or Rashed hospital in Dubai. We obtained written informed consent from
all participants. Inclusion criteria were UAE residency and an age of 18 years or older.
Blood samples and nasal swabs were collected for examination. Of 522 participants, 58 had
missing data for body mass index (BMI; kilograms per square meter of body surface area),
so only 464 were included for data analysis. A flow chart for the selection of participants is
shown in Figure 1. This study was approved by the Abu Dhabi Health COVID-19 Research
Ethics Committee (DOH/DQD/2020/538), the Dubai Scientific Research Ethics Committee
(DSREC-04/2020_09), and the SEHA Research Ethics Committee (SEHA-IRB-005).
2.2. Collecting Demographic Data
Demographic, clinical, and outcome data of COVID-19 patients were gathered from
questionnaires administered by medical staff at the hospital. Health care providers assessed
patients for discharge, including determining disease severity (mild, moderate, or severe).
Smoking status was coded as current smoker or nonsmoker. Chest X-ray and/or computed
tomography scans were performed in all COVID-19 patients. Concerning immunomodula-
tory therapy, patients were selected for tocilizumab according to our institutional protocol.
The endpoint variable for COVID-19 severity was defined as admission to the intensive
care unit, requirement of mechanical ventilation, or death.
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2.3. Extracting and Quantifying SARS-CoV-2 Viral RNA
An experienced phlebotomy nurse collected blood. A total of 2 mL of blood was
collected from the cubital vein by using a gold-top (serum separator) tube. Samples were
stored in a sealed biohazard bag and transported at 4 ◦C in a cool transport container to
the Khalifa University Center for Biotechnology’s laboratory for a second confirmatory
testing for SARS-CoV-2. Viral RNA was extracted from swab by using the Miracle-AutoXT
Automated Nucleic Acid Extraction System (iNtRON Biotechnology, Seoul, South Korea).
Genesig from the Primerdesign reverse transcription-PCR COVID-19 detection kit (Watch-
moor Point, UK) was used to quantify the viral RNA. PCRs were performed according to
the manufacturer’s instructions. Quantitative reverse transcription-PCR was performed
using the Magnetic Induction Cycler PCR Machine (MiC) (Bio Molecular Systems, Queens-
land, Australia).
2.4. Measuring Ser m 25(OH)D Levels
To assess vitamin D status, we measured the levels of total 25(OH)D. At recruitment,
serum samples (that were collected from participants immediately upon arrival to testing
centers) were cryopreserved at –80 ◦C in gel tubes and were used to measure 25(OH)D
concentrations with automated electrochemiluminescence (Elecsys 2010; Roche Diagnostics,
GmbH, Mannheim, Germany). The detection limit of serum 25(OH)D was 4 ng/mL. The
intra-assay coefficient of variation was 5%, and the interassay coefficient was 7.5%.
2.5. Defining Severity of Infection
Clinical assessments of participants included determining the severity (mild, moderate,
or severe) and diagnosis of pneumonia, confirmed using a chest X-ray. Although participants
who presented with mild or no symptoms did not require hospitalization, they were
included in the study because they tested positive for SARS-CoV-2. The mod rate group
had symptoms such as fever, cough, and pneumonia, requiring hospitalization. The severe
group presented with critical clinical features, such as high temperature, cough, pneumonia,
and shortness of breath, requiring intensive care (World Health Organization, 2020).
2.6. Statistical Analysis
Data were analyzed using SPSS version 27.0 (IBM, Armonk, NY, USA). Categorical
variables were presented as frequencies and percentages. Continuous variables were
presented as mean ± standard deviation. Patients were grouped into three categories of
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serum 25(OH)D levels: <12 ng/mL, 12–20 ng/mL, and ≥20 ng/mL. Differences according
to SARS-CoV-2 severity of infection (asymptomatic, mild, moderate, high) were compared
using the chi-square test for categorical variables and one-way analysis of variance for
continuous variables. Moreover, differences based on mortality (deceased, alive) were
explored using the chi-square test or Fisher’s exact test for categorical variables and
independent-samples t-test for continuous variables. Simple and multivariate ordered
logistic regression models were constructed to determine predictors of infection severity.
Simple and multivariate binary logistic regression models were considered to identify
variables associated with mortality. Associations between risk factors and outcomes were
presented as ORs and 95% CIs, with p < 0.05 considered statistically significant.
3. Results
We included 464 participants for data analysis and excluded 58 because of missing
BMI data. Table 1 summarizes the main demographic and clinical characteristics of par-
ticipants according to SARS-CoV-2 severity of infection and mortality. The mean age was
47 ± 15 years, with more than 60% of patients being male. Significant differences were
observed for age, nationality, chronic disease (type 2 diabetes mellitus (T2D), cardiac dis-
ease, and renal disease), smoking, and BMI. The main comorbidities, T2D (32.8%), cardiac
disease (11.6%), and renal disease (8.8%), were more prevalent among patients in the severe
category. Similarly, those patients were older and more obese than others who had either
asymptomatic or mild or moderate COVID-19. About 59% of patients who had vitamin D
deficiency and severe vitamin D deficiency had severe symptoms of COVID-19 infection.
A total of 155 (33.4%) patients were vitamin D sufficient, whereas others were either
deficient or severely deficient. In total, 65 (14%) UAE nationals were included in the study,
of whom 25 (38.5%) had severe infection. The number of Southeast Asian patients was 276
and accounted for 59.5% of all patients, with 72 (26.1%) severely affected by COVID-19.
In addition, patients who had severe infection were older and more obese than others
(p < 0.001). We also evaluated differences in demographics and clinical investigations for
patients according to mortality (Table 1). The baseline features differed significantly only
in terms of age and major comorbidities. A total of 26 (5.6%) of 464 subjects died.
In Table 2, predictors for severity of infection were determined using multivariate or-
dered logistic regression analysis with both the adjusted and unadjusted models. To adjust
for confounding factors, we used two models: model 1 adjusted for age, sex, and smoking,
whereas model 2 adjusted for age, sex, smoking, and comorbidities. BMI > 30 kg/m2
(obesity) was significant in the unadjusted model (OR = 2.42 (95% CI, 1.68, 3.49); p < 0.001).
That factor was not included in the adjusted model. Patients’ sex was not a significant
risk factor, whereas smoking and comorbidities lost significance of effect upon adjustment.
By contrast, age stood out as a strong independent predictor in both models 1 (OR = 1.08
(95% CI, 1.07, 1.10); p < 0.001) and 2 (OR = 1.07 (95% CI, 1.06, 1.09); p < 0.001). Serum
25(OH)D levels of < 12 ng/mL in model 1 (OR = 1.79 (95% CI, 1.21, 2.64); p = 0.003) and
model 2 (OR = 1.76 (95% CI, 1.19, 2.61); p = 0.005) were strongly associated with severity
of COVID-19.
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Table 1. Characteristics of COVID-19 patients according to disease severity and mortality.
Severity Mortality
N Asymptomatic Mild Moderate High p Alive Deceased p
Total 464 91 (19.6) 99 (21.3) 129 (27.8) 145 (31.3) 438 (94.4) 26 (5.6)
Age (years) 46.6 ± 14.9 34.3 ± 7.2 41.6 ± 13.7 49.0 ± 13.0 55.7 ± 14.1 <0.001 45.7 ± 14.5 62.5 ± 13.1 <0.001
Sex
Female 92 (19.8) 27 (29.3) 20 (21.7) 14 (15.2) 31 (33.7) 0.006 89 (96.7) 3 (3.3) 0.28
Male 372 (80.2) 64 (17.2) 79 (21.2) 115 (30.9) 114 (30.6) 349 (93.8) 23 (6.2)
BMI (kg/m2) 28.1 ± 5.9 25.6 ± 4.0 27.0 ± 5.4 28.3 ± 5.4 30.2 ± 6.8 <0.001 28.0 ± 5.7 30.2 ± 8.5 0.07
Obesity (BMI > 30 kg/m2)
Obese 136 (29.3) 11 (8.1) 23 (16.9) 44 (32.4) 58 (42.6) <0.001 128 (94.1) 8 (5.9) 0.89
Not obese 328 (70.7) 80 (24.4) 76 (23.2) 85 (25.9) 87 (26.5) 310 (94.5) 18 (5.5)
Nationality
UAE 65 (14) 0 (0) 13 (20) 27 (41.5) 25 (38.5) <0.001 59 (90.8) 6 (9.2) 0.25
Arab (Middle Eastern) 103 (22.2) 8 (7.8) 41 (39.8) 17 (16.5) 37 (35.9) 97 (94.2) 6 (5.8)
Asian 276 (59.5) 81 (29.3) 44 (15.9) 79 (28.6) 72 (26.1) 264 (95.7) 12 (4.3)
Others 20 (4.3) 2 (10) 1 (5) 6 (30) 11 (55) 18 (90) 2 (10)
Current Smoker
Yes 50 (10.8) 13 (26) 23 (46) 11 (22) 3 (6) <0.001 50 (100) 0 (0) 0.10
No 414 (89.2) 78 (18.8) 76 (18.4) 118 (28.5) 142 (34.3) 388 (93.7) 26 (6.3)
25(OH)D Level (ng/mL)
<12 127 (27.4) 21 (16.5) 28 (22) 34 (26.8) 44 (34.6) 0.07 117 (92.1) 10 (7.9) 0.32
12–20 182 (39.2) 48 (26.4) 36 (19.8) 53 (29.1) 45 (24.7) 175 (96.2) 7 (3.8)
≥20 155 (33.4) 22 (14.2) 35 (22.6) 42 (27.1) 56 (36.1) 146 (94.2) 9 (5.8)
Cardiac Disease
Yes 54 (11.6) 0 (0) 10 (18.5) 16 (29.6) 28 (51.9) <0.001 44 (81.5) 10 (18.5) <0.001
No 410 (88.4) 91 (22.2) 89 (21.7) 113 (27.6) 117 (28.5) 394 (96.1) 16 (3.9)
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Table 1. Cont.
Severity Mortality
N Asymptomatic Mild Moderate High p Alive Deceased p
Chronic Lung Disease
Yes 24 (5.2) 0 (0) 2 (8.3) 8 (33.3) 14 (58.3) 0.004 20 (83.3) 4 (16.7) 0.04
No 439 (94.8) 91 (20.7) 97 (22.1) 120 (27.3) 131 (29.8) 417 (95) 22 (5)
Diabetes
Yes 152 (32.8) 4 (2.6) 23 (15.1) 56 (36.8) 69 (45.4) <0.001 136 (89.5) 16 (10.5) 0.001
No 312 (67.2) 87 (27.9) 76 (24.4) 73 (23.4) 76 (24.4) 302 (96.8) 10 (3.2)
Renal Disease
Yes 41 (8.8) 0 (0) 3 (7.3) 12 (29.3) 26 (63.4) <0.001 33 (80.5) 8 (19.5) <0.001
No 423 (91.2) 91 (21.5) 96 (22.7) 117 (27.7) 119 (28.1) 405 (95.7) 18 (4.3)
Metabolic Disease
Yes 27 (5.8) 1 (3.7) 4 (14.8) 8 (29.6) 14 (51.9) 0.04 23 (85.2) 4 (14.8) 0.06
No 437 (94.2) 90 (20.6) 95 (21.7) 121 (27.7) 131 (30) 415 (95) 22 (5)
Liver Disease
Yes 7 (1.5) 0 (0) 1 (14.3) 2 (28.6) 4 (57.1) 0.41 6 (85.7) 1 (14.3) 0.33
No 457 (98.5) 91 (19.9) 98 (21.4) 127 (27.8) 141 (30.9) 432 (94.5) 25 (5.5)
Data are presented as N (%); data presented as mean ± SD; BMI, body mass index; UAE, United Arab Emirates; 25(OH)D, serum 25-hydroxyvitamin D; p < 0.05 considered significant (shown in boldface).
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Table 2. Predictors for COVID-19 severity using multivariate ordered logistic regression analysis.
Model 1 Model 2
Unadjusted Adjusted Adjusted
Predictor OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 1.08 (1.07, 1.10) <0.001 1.08 (1.07, 1.10) <0.001 1.07 (1.06, 1.09) <0.001
Male 1.39 (0.91, 2.14) 0.13 1.22 (0.78, 1.91) 0.38 1.23 (0.78, 1.94) 0.38
Smoker 0.34 (0.21, 0.57) <0.001 0.60 (0.35, 1.02) 0.06 0.60 (0.35, 1.02) 0.06
Obese (BMI > 30 kg/m2) 2.42 (1.68, 3.49) <0.001
Cardiac Disease 3.11 (1.84, 5.26) <0.001 0.72 (0.38, 1.37) 0.32
Chronic Lung Disease 3.96 (1.81, 8.67) 0.001 1.64 (0.68, 3.93) 0.27
Diabetes 3.68 (2.56, 5.29) <0.001 1.27 (0.82, 1.97) 0.28
Renal Disease 5.13 (2.71, 9.73) <0.001 1.66 (0.80, 3.48) 0.18
Metabolic Disease 2.79 (1.35, 5.75) 0.005 1.34 (0.60, 2.99) 0.45
Liver Disease 3.35 (0.81, 13.85) 0.10 2.99 (0.54, 16.52) 0.21
25(OH)D < 12 ng/mL 1.22 (0.84, 1.76) 0.29 1.79 (1.21, 2.64) 0.003 1.76 (1.19, 2.61) 0.005
25(OH)D < 20 ng/mL 0.71 (0.50, 1.00) 0.051 1.17 (0.80, 1.71) 0.41 1.14 (0.78, 1.66) 0.51
Model 1 is adjusted for age, sex, and smoking status. Model 2 is adjusted for age, sex, smoking status, and comorbidities. Data are presented
as frequencies (%) and odds ratio (OR) (95% CI); BMI, body mass index; 25(OH)D, serum 25-hydroxyvitamin D; p < 0.05 considered
significant (shown in boldface).
Predictors for mortality, obtained using binary regression analysis with the outcomes
of deceased or alive, are shown in Table 3. Age was strongly associated with risk of
mortality. The only other significant predictor in the adjusted model was serum 25(OH)D
levels < 12 ng/mL, which were associated with 2.55 times higher risk for death upon
adjustment for age and sex (OR = 2.55 (95% CI, 1.03, 6.33); p = 0.04) and 2.58 times higher risk
for death upon adjustment for age, sex, and comorbidities (OR = 2.58 (95% CI, 1.01, 6.62);
p = 0.048). Major comorbidities were risk factors in the unadjusted models only. No
deceased case patients were smokers; hence, smoking as a risk factor for mortality was
not applicable. BMI > 30 kg/m2 was not correlated with risk of death in the unadjusted
model. For model 2, obesity was utilized in the unadjusted model only and excluded
from the adjusted because there is a strong inverse correlation between 25(OH)D and
BMI, and confounding factors that affect the factor of interest should not be included for
adjustment [36,37].
Table 3. Significant predictors of mortality, using binary logistic regression analysis.
Model (1) Model (2)
Unadjusted Adjusted Adjusted
Predictor OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 1.08 (1.05, 1.11) <0.001 1.08 (1.05, 1.12) 0.001 1.07 (1.03, 1.11) 0.001
Male 1.96 (0.57, 6.66) 0.28 1.67 (0.46, 6.02) 0.43 1.84 (0.47, 7.25) 0.38
Smoker NA
Obese (BMI > 30 kg/m2) 1.08 (0.46, 2.54) 0.87
Cardiac Disease 5.60 (2.39, 13.08) <0.001 1.66 (0.57, 4.83) 0.35
Chronic Lung Disease 3.79 (1.19, 12.04) 0.02 1.12 (0.28, 4.41) 0.87
Diabetes 3.55 (1.57, 8.03) 0.002 0.99 (0.38, 2.58) 0.98
Renal Disease 5.45 (2.21, 13.49) <0.001 1.33 (0.45, 3.95) 0.60
Metabolic Disease 3.28 (1.04, 10.31) 0.04 2.45 (0.64, 9.34) 0.19
Liver Disease 2.88 (0.33, 24.85) 0.34 1.66 (0.16, 17.41) 0.67
25(OH)D < 12 ng/mL 1.71 (0.76, 3.89) 0.20 2.55 (1.03, 6.33) 0.04 2.58 (1.01, 6.62) 0.048
25(OH)D < 20 ng/mL 0.94 (0.41, 2.17) 0.89 1.72 (0.68, 4.34) 0.25 1.71 (0.66, 4.43) 0.27
Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, and comorbidities. Data are presented as frequencies (%) and odds
ratio (OR) (95% CI); BMI, body mass index; 25(OH)D, serum 25-hydroxyvitamin D; p < 0.05 considered significant (shown in boldface).
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4. Discussion
Several recent reviews highlighted the important role of micronutrients in supporting
the immune system and, hence, potentially reducing the risk of COVID-19 infection.
Among those, vitamin D is the most attractive for research [38–40].
In our study, serum 25(OH)D levels were associated with severity of COVID-19
infection after adjustment for the main confounding factors, namely, age and sex. The
protective effect for vitamin D supplementation against viral respiratory infections has
been well established, and similar results have started to emerge for COVID-19 [7]. Age
was strongly associated with severity and mortality. Our results are in accordance with
other observational studies indicating that vitamin D deficiency is significantly associated
with COVID-19 severity and death [7]. Age, obesity, and vitamin D deficiency have been
well-established risk factors for COVID-19 infection [41]. Aging, also known as senescence,
is a complex phenomenon involving many changes in all physiological systems [42–44].
The immune system is one system that exhibits several changes during the life span [45–48].
Being an intricate system that protects the body from external and internal invaders makes
it of particular interest to study in the context of aging. Immunosenescence is a term that
encompasses the major changes that happen to the immune system during aging, which is
characterized by a drop in various immune variables. Recent studies suggest that the most
featured changes that happen during aging in the adaptive immune system define the state
of immunosenescence [49,50]. One of the most important perceptions in recent years is that
the innate immune system has a type of memory, called trained innate immune memory,
which at least partially illustrates some of the immune-related features of aging [51,52].
The suggestion of trained innate memory may clarify why aging innate immune cells stay
activated [53]. Another study suggests that this state of activation is maintained even in
the absence of a specific challenge [47]. The chronic low-grade inflammation (inflamm-
aging) is responsible for maintaining immune cells in the activation state. In addition,
anti-inflammatory molecules are needed during aging to balance that state, the destruction
of which may destroy the whole creature [54].
The association between vitamin D status at time of hospitalization and sequels of
acute inflammatory illness could be bidirectional. Even though inflammation could lower
the level of serum 25(OH), the immunomodulatory effects of vitamin D are probably the
results of its long-term rather than short-term actions [55]. Serum 25(OH)D concentrations
decrease near the onset of acute inflammatory illnesses. However, the effect appears short-
lived, perhaps only for a few hours [56]. Obesity is another notable factor that has been
profoundly associated with COVID-19 risk [57–62]. However, recent studies indicate that
BMI should be used in the models with confounders to interpret COVID-19 outcomes [57].
The UAE has abundant sunlight throughout most of the year, yet the population
is mostly deficient owing to several risk factors, including style of dress and avoidance
of sun exposure [33,34]. A retrospective study of 60,979 people from the UAE reported
the mean value for serum 25(OH)D to be 48.89 nmol/L. Overall, 82% of those examined
presented with hypovitaminosis, of whom 26% of females and 18% of males had severe
deficiency. That research showed the serious magnitude of this public health burden
among the UAE population [34]. The use of vitamin D supplementation with different
attitudes toward medical screening and sun exposure upon the incidental identification
of vitamin D deficiency during treatment for other conditions among middle-aged and
older adults prompted a robust recommendation for supplementation [61]. UAE health
care professionals regularly prescribe supplementation for patients with chronic illnesses,
including T2D, cardiovascular diseases, and hypertension. Recently, UAE health insurers
have excluded vitamin D tests from coverage among the annual health screen for apparently
healthy people, resulting in a resurgence of vitamin D deficiency among young adults
in comparison with older adults [61]. Our results are in accordance with previous data
reported by Haq and colleagues [34]. Their results showed lower mean serum 25(OH)D
for the 33–44 age group than for participants 45 and older—most likely because that
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subpopulation uses supplementation prescribed by health professionals during medical
consultation visits.
Our findings reveal strong implications for vitamin D supplementation not only as
a preventive strategy against COVID-19 infection, but also to boost immunity during
infection. Accumulating positive results about vitamin D supplementation from several
RCTs and intervention-based studies prove that supplementation goes beyond simply
addressing vitamin D deficiency to being a protective and maybe even therapeutic mea-
sure [26]. Many observational studies have reported the strong link between vitamin D
status and risk of disease severity among COVID-19 patients. A meta-analysis of 27 studies
reported that vitamin D deficiency in patients with COVID-19 was significantly associ-
ated with higher risks of severe infection (OR = 1.64; 95% CI, 1.30, 2.09), hospitalization
(OR = 1.81; 95% CI, 1.42, 2.21), and mortality (OR = 1.92; 95% CI, 1.06, 2.58) [63]. Many
studies worldwide have investigated the same research question but reached inconsistent
and non-decisive results, possibly due to different patient characteristics and research de-
signs. A retrospective observational study to determine the positivity rate for SARS-CoV-2
among more than 190,000 patients in the United States estimated seroprevalence to be 9.3%
among the population and revealed a significant inverse association with serum 25(OH)D
levels independent of latitude, ethnicity, age, and sex [64]. One plausible explanation for
the putative protective role of vitamin D and adequate serum 25(OH) against COVID-19
was linked to the compound nitric oxide (NO), which is an important component of the
body’s antiviral defense mechanism [65]. NO inhibits replication of SARS-CoV-2 [66] and
inactivates or modifies viral replicating proteins [67]. Calcitriol is a direct transcriptional
regulator of endothelial NO synthase, the primary source of NO in the blood. NO reduces
risk of arterial stiffness, an important risk factor for hypertension [68]. Hypertension is
an important risk factor for COVID-19, and UV exposure can reduce blood pressure [69].
Similar research from the Middle East region and Gulf countries is limited. A compre-
hensive study in Israel among 14,000 participants showed that vitamin D deficiency was
a strong risk factor for COVID-19 infection [70]. Another study among 73 seropositive
Iranian patients showed that vitamin D deficiency correlated with mortality [71]. A recent
investigation in Saudi Arabia showed a robust association for severe vitamin D deficiency
with death but not severity of disease [72]. In a different case–control study in the same
country, 138 mildly affected patients were matched with 82 negative controls, and serum
25(OH)D levels were significantly lower in affected people but were not a predictor of
disease outcome. That finding called for additional large population-based RCTs to further
confirm the results [73].
5. Strengths and Limitations
To our knowledge, this is the first study to evaluate 25(OH)D levels in patients who
tested positive for SARS-CoV-2 and to examine their association with COVID-19 severity
and mortality among a sample of affected people within the UAE. Our findings offer
promising results that warrant further research to examine whether vitamin D supple-
mentation could help reduce COVID-19 severity and risk of infection in this population.
Vitamin D deficiency is often associated with several comorbidities such as cardiometabolic
disorders, T2D, and obesity. The use of multivariate analysis to control for confounding
variables and the fact that we recruited subjects from two main hospitals in the UAE’s
two main cities (Abu Dhabi and Dubai) strengthened our investigation. Moreover, all
nationalities were included to reflect the multiethnic UAE population.
Some limitations are worth noting, however. The small number of deaths in our study
most likely affected the analysis. Examining a larger sample to include more mortalities
could offer more conclusive results about the relation between vitamin D status and the
death outcome from COVID-19 infection in the UAE. The socioeconomic status for all
participants was not assessed, but could have affected the dietary habits and availability of
fortified foods, which in turn could have affected vitamin D status along with any use of
supplements and sun exposure that were not recorded. In addition, the optimal concentra-
Nutrients 2021, 13, 1714 11 of 14
tion of serum 25(OH)D for overall health remains controversial and using different cutoffs
might slightly change results. The bone-centric guidelines recommend a target 25(OH)D
concentration of 20 ng/mL (50 nmol/L) and age-dependent daily vitamin D doses of
400–800 IU. The guidelines focused on the pleiotropic effects of vitamin D recommend a
target 25(OH)D concentration of 30 ng/mL (75 nmol/L) and age-, body weight-, disease
status-, and ethnicity-dependent vitamin D doses between 400 and 2000 IU/day [74]. How-
ever, mounting evidence indicates that optimal 25(OH)D levels are 40–60 ng/mL, as seen
in the SARS-CoV-2 seropositivity study by Kaufman and colleagues [64], an open-label
vitamin D supplementation-breast cancer incidence study [75], and an open-label vitamin
D supplementation-blood pressure study [76].
6. Conclusions
Our data showed that serum 25(OH)D levels <12 ng/mL are strongly associated with
COVID-19 severity and mortality among a sample of affected people in the UAE. Such
findings suggest important implications that vitamin D supplementation could help reduce
the severity of COVID-19 disease and risk of infection. Further larger observational studies
and RCTs are needed to furnish a comprehensive picture about the link between vitamin D
and COVID-19 severity and death among the UAE population.
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